CollectionsAstrazeneca Plc
IN THE NEWS

Astrazeneca Plc

FEATURED ARTICLES
BUSINESS
December 16, 2012
In the Region Fewer PGW terminations Philadelphia Gas Works said Friday that 7,742 of its 479,000 residential customers are without gas service after their accounts were terminated earlier in the year for failure to pay, a reduction of 781 customers from the same time a year ago. The city-owned utility reported the numbers in its annual cold weather survey that it is required to submit to the Pennsylvania Public Utility Commission....
NEWS
April 15, 2008 | By Jane Wardell, ASSOCIATED PRESS
LONDON - Shares in pharmaceutical company AstraZeneca PLC soared today on news that an agreement with an Indian company will delay the release of a generic competitor to its best selling heartburn drug for six years. AstraZeneca said financial guidance for 2008 would remain unchanged, but the company's shares shot up almost 9 percent as analysts sensed less of a profit risk for the London-based drug maker. India's Ranbaxy Laboratories Ltd. had submitted an application to the U.S. Food and Drug Administration to make a generic version of esomeprazole magnesium, the active pharmaceutical ingredient in heartburn medicine Nexium.
BUSINESS
October 7, 2011 | By David Sell, Inquirer Staff Writer
AstraZeneca P.L.C., the global pharmaceutical giant that makes well-known medicines such as Prilosec, Nexium, and Seroquel, said Thursday it would cut about 400 U.S. jobs, with most of the layoffs at its headquarters in Wilmington. About 330 people will lose jobs and 70 vacant positions will be eliminated as the company continues to pare its costs to sustain profits. The company said the job cuts would come from headquarters staff and "some field-based, non-sales roles," elsewhere in the country.
BUSINESS
April 26, 2012 | By David Sell, INQUIRER STAFF WRITER
AstraZeneca P.L.C. chief executive officer David Brennan said Thursday he would retire June 1 in the wake of another difficult quarter for the pharmaceutical manufacturer. Based in the United Kingdom, AstraZeneca has its U.S. headquarters in Wilmington and a plant in Newark, Del. The company has struggled lately as it tried to replace revenue, some of which has been lost as blockbuster drugs face generic competition because their patents are expiring. AstraZeneca's best-selling drugs are Crestor (cardiovascular)
BUSINESS
October 20, 2000 | By Susan Warner, INQUIRER STAFF WRITER
It is the world's best-selling prescription drug, and for some, the bright purple pill Prilosec has become a daily essential they call Vitamin P. And like vitamins, Prilosec may soon be available without a prescription. Today, AstraZeneca P.L.C., the British drugmaker with U.S. headquarters in Wilmington, will go before a Food and Drug Administration committee to seek approval to sell an over-the-counter version of its Prilosec, a treatment for such stomach disorders as ulcers and heartburn.
BUSINESS
April 24, 2007 | By Linda Loyd INQUIRER STAFF WRITER
After a series of setbacks in developing products, AstraZeneca P.L.C. said today that it would pay $15.2 billion in cash to buy MedImmune Inc. in order to gain biotechnology medicines and enter the vaccines business. AstraZeneca - Britain's second-largest drugmaker, with U.S. headquarters and about 4,500 employees near Wilmington - will pay $58 a share for MedImmune, which is a 21 percent premium to the Gaithersburg, Md., company's closing price Friday of $48.01. The deal will increase AstraZeneca's proportion of biologics drugs, derived from organisms, from 7 percent to 27 percent, add 45 products in development, and give AstraZeneca the influenza vaccine FluMist and the children's respiratory treatment Synagis.
NEWS
April 9, 2009 | By Miriam Hill, INQUIRER STAFF WRITER
A government panel opened the door a crack yesterday toward allowing AstraZeneca P.L.C. to sell its Seroquel XR more widely, after an emotional meeting that included stories from two families who say their loved ones died after taking the powerful antipsychotic. The Food and Drug Administration advisory committee recommended the agency approve Seroquel XR for use as an additional therapy in patients suffering from depression who do not respond adequately to their current medications.
BUSINESS
April 26, 2011 | By Mike Armstrong, Inquirer Columnist
When I'd heard that AstraZeneca P.L.C. was not only cutting jobs in Wilmington, but also tearing down buildings, it sounded like a corporate variation on scorched-earth tactics. The News Journal broke the news last week that the pharmaceutical company plans to raze 450,000 square feet of laboratory space in three buildings at its Wilmington-area campus over the next two years. Most companies, when they resort to layoffs, don't level the buildings, too. It sounded to me to be a little drastic.
BUSINESS
May 3, 2007 | By Thomas Ginsberg INQUIRER STAFF WRITER
Federal regulators said yesterday that they are reviewing AstraZeneca P.L.C.'s handling of alleged improper marketing and the firing of a sales director. The U.S. Department of Health and Human Services made the comment in response to the drug company's statement yesterday that it had concluded an internal investigation and would share findings with regulators. "We expect to receive further information from AstraZeneca and will follow up with them as appropriate," a department spokesman, Donald White, said, giving no more details.
BUSINESS
July 27, 2007 | By Linda Loyd INQUIRER STAFF WRITER
AstraZeneca P.L.C. said yesterday that it would lay off an additional 4,600 employees, trimming its payroll 7,600, or 11 percent of its workforce, within three years. The London-based drugmaker announced in February that it would dismiss about 3,000 employees in operations and manufacturing. The company said it decided additional cuts were needed in European sales and marketing, information services and business support, and drug research and development. "We still haven't finished exploring further opportunities to reduce our cost base and improve future profitability," chief financial officer Jon Symonds told investors and analysts.
1 | 2 | 3 | 4 | 5 | Next »
ARTICLES BY DATE
BUSINESS
December 16, 2012
In the Region Fewer PGW terminations Philadelphia Gas Works said Friday that 7,742 of its 479,000 residential customers are without gas service after their accounts were terminated earlier in the year for failure to pay, a reduction of 781 customers from the same time a year ago. The city-owned utility reported the numbers in its annual cold weather survey that it is required to submit to the Pennsylvania Public Utility Commission....
BUSINESS
October 27, 2012 | By David Sell, Inquirer Staff Writer
AstraZeneca P.L.C., which is based in the United Kingdom but has a big operation in Wilmington, said its third-quarter profit dropped more than 50 percent, indicating the challenge ahead for new chief executive officer Pascal Soriot. "We are facing patent challenges for some products, but we have growth platforms," Soriot said in a conference call Thursday. Soriot departed Roche and stepped into his new job on Oct. 1. Right away, he stopped a stock buyback program to preserve cash.
BUSINESS
July 28, 2012 | By David Sell, Inquirer Staff Writer
Pharmaceutical companies, like banks, are more dependent upon governments than many people realize, and the European economic crisis that has worried global bank-watchers for several years is increasingly causing concern for drug executives. Governments in the United States, Europe, and much of the world pay many of the bills for pills and other medicine. Government budget-tightening, whatever the cause, has meant reductions in prices paid to drug manufacturers, and that has shown up this week in quarterly earnings reports.
BUSINESS
April 26, 2012 | By David Sell, INQUIRER STAFF WRITER
AstraZeneca P.L.C. chief executive officer David Brennan said Thursday he would retire June 1 in the wake of another difficult quarter for the pharmaceutical manufacturer. Based in the United Kingdom, AstraZeneca has its U.S. headquarters in Wilmington and a plant in Newark, Del. The company has struggled lately as it tried to replace revenue, some of which has been lost as blockbuster drugs face generic competition because their patents are expiring. AstraZeneca's best-selling drugs are Crestor (cardiovascular)
BUSINESS
April 24, 2012 | By David Sell, INQUIRER STAFF WRITER
Pfizer is intent on shedding noncore businesses. AstraZeneca is intent on adding any small company that might bring revenue. Such were underlying motivations for billion-dollar deals announced Monday by the two pharmaceutical giants, both of which have operations in the Philadelphia region. Pfizer Inc. sold its infant nutrition division to Nestle SA for $11.85 billion while AstraZeneca P.L.C. spent $1.26 billion to buy San Diego-based Ardea Biosciences Inc., which has a promising, but not-yet-ready, medicine for gout.
BUSINESS
December 21, 2011 | By Mike Armstrong, Inquirer Columnist
Accountable-care organizations, or ACOs, may be the ghost of health-care future for most Americans. For Wayne-based Renaissance Medical Management Co. , the designation is an opportunity to expand its model to a new patient population, starting Jan. 1. Renaissance Medical was selected by the federal Centers for Medicare & Medicaid Services on Monday to participate in its Pioneer Accountable Care Organizations initiative....
BUSINESS
October 7, 2011 | By David Sell, Inquirer Staff Writer
AstraZeneca P.L.C., the global pharmaceutical giant that makes well-known medicines such as Prilosec, Nexium, and Seroquel, said Thursday it would cut about 400 U.S. jobs, with most of the layoffs at its headquarters in Wilmington. About 330 people will lose jobs and 70 vacant positions will be eliminated as the company continues to pare its costs to sustain profits. The company said the job cuts would come from headquarters staff and "some field-based, non-sales roles," elsewhere in the country.
NEWS
October 6, 2011 | By David Sell, INQUIRER STAFF WRITER
AstraZeneca P.L.C., the global pharmaceutical giant that makes well-known medicines such as Prilosec, Nexium and Seroquel, said Thursday that it will cut about 400 U.S. jobs, with most of the layoffs occurring at its headquarters in Wilmington. About 330 people will lose jobs and 70 vacant positions will be eliminated as the company continues to pare its costs to sustain profits. The company said the job cuts would come from headquarters staff and "some field-based, non-sales roles," elsewhere in the country.
1 | 2 | 3 | 4 | 5 | Next »
|
|
|
|
|